palopegteriparatide · Yorvipath
Peptide
Evidence outlook
Approved: Hypoparathyroidism
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Chronic hypoparathyroidism in adults (Great Britain)
- Adults with chronic hypoparathyroidism
- Hypoparathyroidism (Teijin Pharma)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PaTHway60 NCT07081997 · Hypoparathyroidism Registry: NCT07081997 | 3 | Efficacy - Primary endpoint (26 weeks) 2027-06 | In progress: results expected 1 Jun 2027 | not yet graded | link ↗ |
View 2 more trials
NCT07706764 NCT07706764 · Hypoparathyroidism Registry: NCT07706764 | 3 | Percentage of participants meeting the multicomponent efficacy endpoint at Week 26 (26 weeks) 2027-08 | In progress: results expected 1 Aug 2027 | not yet graded | link ↗ |
PaTHway NCT04701203 · Hypoparathyroidism This was a randomized, quadruple-blind, placebo-controlled phase 3 trial, and its primary endpoint, normal serum calcium with independence from active vitamin D and therapeutic calcium at Week 26, was met (78.7% vs 4.8%, p<0.0001). A sample-size calculation required 68 randomized participants (76 allowing for dropout), and 84 were enrolled. Registry: NCT04701203 | 3 | Efficacy - Primary Endpoint During the Blinded Period (26 weeks) 2022-01-12 | Efficacy - Primary Endpoint During the Blinded Period (26 weeks): TransCon PTH 78.7 Percentage of participants (95% CI 66.3 to 88.1) | Placebo 4.8 Percentage of participants (95% CI 0.1 to 23.8) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Hypoparathyroidism: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Palopegteriparatide (Yorvipath): this drug | Approved | Peptide | PTH1 receptor (PTH replacement) | Reliable signal | NCT04701203: Efficacy - Primary Endpoint During the Blinded Period (26 weeks): TransCon PTH 78.7 Percentage of participants (95% CI 66.3 to 88.1) | Placebo 4.8 Percentage of participants (95% CI 0.1 to 23.8) | |
| Eneboparatide | Phase 3 | Peptide | Parathyroid hormone receptor 1 (PTH1R) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Yorvipath (palopegteriparatide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.